NCT00440765View on ClinicalTrials.gov

VALEO: A Post Authorization Study, Designed to Learn More About the Safety and Effectiveness of the Use of Bortezomib in the Netherlands

CompletedOBSERVATIONAL

Enrollment

331

Participants

Timeline

Start Date

November 30, 2004

Primary Completion Date

January 31, 2012

Study Completion Date

January 31, 2012

Conditions

Multiple MyelomaHematological Neoplasms

Interventions

DRUG

bortezomib

dose as determined (observational study) by treating physician

Trial Locations (44)

Unknown

's-Hertogenbosch

Alkmaar

Amersfoort

Amstelveen

Amsterdam-Zuidoost

Apeldoorn

Bergen op Zoom

Blaricum

Breda

Capelle Aan Den Ijss

Delfzijl

Deventer

Dirksland

Doetinchem

Dordrecht

Drachten

Ede Gld

Eindhoven

Flushing

Geldrop

Goes

Gouda

Groningen

Hardenberg

Heerenveen

Hoofddorp

Hoogeveen

Leiden

Maastricht

Nieuwegein

Nijmegen

Oss

Roosendaal

Rotterdam

Schiedam

Terneuzen

The Hague

Tilburg

Utrecht

Veghel

Veldhoven

Woerden

Zaandam

Zutphen

All Listed Sponsors

lead

Janssen-Cilag B.V.

INDUSTRY

NCT00440765 - VALEO: A Post Authorization Study, Designed to Learn More About the Safety and Effectiveness of the Use of Bortezomib in the Netherlands | Biotech Hunter | Biotech Hunter